-inc-logo-1200x675.png){kind=logo}
Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report) shares traded down 2.6% on Friday. The company traded as low as $32.8407 and last traded at $34.18. 2,104,433 shares changed hands during trading, a decline of 38% from the average daily volume of 3,376,665 shares. The stock had previously closed at $35.09.
Mind Medicine (MindMed) Stock Down 2.6%
The business’s 50 day moving average price is $40.41 and its 200-day moving average price is $32.83.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing therapies for brain health and psychiatric disorders. The company researches medicines derived from or inspired by psychedelic and empathogenic compounds, with the goal of addressing conditions that may not respond adequately to existing treatments.
MindMed’s lead program, MM120, is an orally administered formulation of lysergide, commonly known as LSD, being evaluated for anxiety and other psychiatric disorders.
Further Reading
- Five stocks we like better than Mind Medicine (MindMed)
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.
